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Abstract
MicroRNAs are non-coding RNAs that negatively regulate mRNA expression
and play significant roles in both health and disease. Differential microRNA
expression has been used to aid diagnosis and discriminate disease stages.
The accuracy and reliability of microRNA expression measurement is of utmost
importance. Quantification of microRNA expression in human peripheral blood
is commonly detected using total RNA extracted via different methods. To date,
no convincing data are available showing whether microRNA quantification
results can be influenced by the use of total RNA extracted from whole blood or
peripheral blood mononuclear cells (PBMCs). This study examined
miR-146a-5p and miR-155-5p expression using total RNA extracted in parallel
from whole blood and PBMCs of 14 healthy volunteers. The data showed that
the quantification of miRNA using total RNA extracted from whole blood varied
from that of PBMCs, indicating that the miRNA expression was a result of all
the different cell-types present in whole blood. Our results suggested that the
source of total RNA and the statistical analyses performed are crucial
considerations when designing miRNA research.
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Introduction
MicroRNAs (miRNAs) are cell- and therefore tissue-specific, and 
their expression levels impact protein translation (Sood et al., 2006). 
Nearly, 2000 microRNA (miRNA) sequences have been identified 
in humans (Kozomara & Griffiths-Jones, 2014). Numerous studies 
have reported specific miRNA expression levels in peripheral blood 
(PB) as markers of disease (Mookherjee & El-Gabalawy, 2013; 
Patnaik et al., 2012). Although miRNA expression levels could 
be inevitably influenced by the way that total RNA is extracted, 
often studies reporting differential miRNA expression levels fail to 
emphasise the impact of RNA extraction methods. This could at 
least partially lead to significant controversies and inconsistencies 
in the literature related to miRNA research.
PAXgene Blood RNA System (PAXgene Blood RNA Tube and 
PAXgene Blood miRNA Kit [PAXM]) has been the gold standard 
for PB collection as the stabilising reagent present in the tube pre-
vents RNA degradation and inhibits changes in gene expression due 
to the collection procedure (Viprey et al., 2012). However, it should 
be emphasised that the miRNA expression detected in whole blood 
is the overall outcome from total hematocytes rather than the lym-
phocyte fraction only. Recent studies have shown that erythrocytes 
also contain a high proportion of miRNAs (Hamilton, 2010). Bayatti 
et al. have shown that the presence of globin (globular proteins such 
as haemoglobin) in PB can impact RNA expression and that globin 
depletion can decrease total RNA quality and yield in particular 
when extraction is performed using the PAXgene Blood RNA 
kit (Bayatti et al., 2014). However, it is necessary to evaluate the 
miRNA expression levels in an independent cohort, as miRNAs are 
in general highly stable, and therefore their expression might not 
be affected by globin treatment. A recent research has reported that 
miRNA expression levels detected using whole blood correlated 
to that of PBMCs when using PAXgene Blood RNA System and 
mirVana miRNA kit (MM), respectively (Mookherjee & El-Gabalawy, 
2013). The study did not show that the expression levels are com-
parable or that they agree with each other using the recommended 
Bland-Altman method comparison statistical test (Bland & Altman, 
1986). This has raised some confusion as the PAXgene Blood RNA 
system extracts from whole blood while MM from PBMCs. Per-
forming a comprehensive statistical analysis is required when two 
methods are compared (Burd, 2010).
In this investigation we have measured the expression of miR-146a-5p 
and miR-155-5p which have extensively been investigated in whole 
blood and PBMCs due to their critical functions in the innate and 
adaptive immune system (Curtale et al., 2010; Schulte et al., 2013). 
We sought to compare miRNA expression levels in peripheral blood 
collected from 14 healthy volunteers using both extraction meth-
ods (PAXM and mirVana PARIS [MP]). We sought to address 
(i) whether miRNA expression detected in whole blood is compa-
rable to that of isolated PBMCs and (ii) to detect the presence of 
haemolysis in whole blood and PBMCs. The experimental design 
for this investigation is depicted in Figure 1.
Materials and methods
Volunteer cohort
Whole blood was collected from 14 healthy volunteers following 
approval from the Newcastle and North Tyneside 2 Research Eth-
ics Committee (STEMDIAGNOSTICS: REC-07/H0906/131) and 
informed consent was obtained from every volunteer for both blood 
collection and miRNA testing. Samples from 14 healthy volunteers 
(5 males and 9 females) were used to quantify miRNA expression 
in whole blood and PBMC.
Sample collection and storage
PB (2.5 ml) was collected in PAXgene Blood RNA Tubes (Pre-
AnalytiX GmbH, Switzerland [Catalog No: 762165]) containing an 
RNA stabilising agent that lysed the blood cells and stabilised the 
intracellular RNA. The tubes were stored at -20°C until processed. 
PB was also collected in sodium (Na)-heparin (Sigma, UK) con-
taining tubes for peripheral blood mononuclear cell isolation using 
graduated centrifugation over Lymphoprep™ (STEMCELL Tech-
nologies, Manchester, UK). The cells were then stored on ice before 
extraction. Isolated PBMCs were cryopreserved by re-suspension in 
freezing solution containing 70% RPMI 1640 (Sigma-Aldrich, UK), 
20% fetal calf serum and 10% dimethyl sulfoxide (NBS Biologicals, 
UK) and stored in Cryovials at -80°C.
      Amendments from Version 3
The difference between this version and the previous one is in the 
methods section - cells were stored on ice, prior to extraction and 
70% RPMI was used in making the freezing solution.
See referee reports
REVISED
Figure 1. Experimental design. Peripheral blood was collected 
into various tubes as illustrated. Total RNA was extracted from whole 
blood using the PAXgene blood miRNA kit and from PBMCs using 
the mirVana Paris and mirVana isolation kits, respectively. The total 
RNA contained the miRNA population which was measured by firstly 
performing reverse transcription and then quantitative real-time 
PCR.
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Total RNA extraction from peripheral blood
Total RNA was extracted from isolated PBMCs using the 
(i) mirVana™ PARIS™ kit (MP) and (ii) mirVana™ miRNA Isola-
tion kit (MM) (Ambion, USA [Catalog Nos: AM1556 and AM1560, 
respectively]) according to the manufacturer’s protocol. PAXgene 
Blood RNA Tubes were incubated overnight at room temperature 
to increase the RNA yield. Total RNA extraction from whole blood 
was performed using the PAXgene Blood miRNA kit (PAXM) (Pre-
AnalytiX GmBh, Switzerland [Catalog No: 763134]), according to 
the manufacturer’s protocol. Aseptic techniques were followed at 
all stages of extraction. Total RNA quality and concentration were 
assessed using NanoDrop ND-1000 spectrophotometer (Thermo 
Fischer Scientific, MA). The absorbance ratios 260 nm/280 nm and 
260 nm/230 nm were analysed to determine the purity of total RNA.
Reverse transcription and quantitative real-time PCR
MicroRNA specific cDNA was synthesised from 10 ng total RNA 
extracted from isolated PBMCs and whole blood using TaqMan 
MicroRNA reverse transcription (RT) kit (Applied Biosystems, 
Life Technologies, USA [Catalog No: 4366596]) as per the manu-
facturer’s protocol. The same RNA concentration was used for all 
the reactions. Hydrolysis probes were used for cDNA synthesis 
(Assay IDs: miR-155-5p-5p: 000479, miR-146a-5p: 000468, miR-
451-5p: 001141, miR-23a-3p: 000399, SNORD49A [RNU49]: 
001005, SNRNP27 [U6]: 001973, SNORA74A [RNU19]: 001003 
and SNORD48 [RNU48]: 001006). No-enzyme control (NEC) and 
a negative template control (NTC) were run for every extraction 
and RT reaction set. The samples were then run on a thermal cycler 
at four different holding temperatures: 16°C for 30 minutes, 42°C 
for 30 minutes, 85°C for 5 minutes and finally at 4°C until storage 
at -4°C.
Quantitative real-time PCR (qPCR) was performed using the TaqMan 
method and hydrolysis probes mentioned above (Applied Biosystems 
by Life Technologies, CA, USA) according to the manufacturer’s pro-
tocol. Each sample was run in triplicate and every plate contained the 
NTC from the RT step and the qPCR step as well as NEC on a 7900HT 
Fast Real-Time PCR System (Life Technologues, CA, USA).
Data analysis
The qPCR results were analysed using SDS v2.4 software and nor-
malised using SNORD48 as the reference control which was selected 
by testing a panel of four controls for stable expression within the 
whole blood and PBMCs. The comparative ∆∆Cq method was used 
to calculate fold-changes (∆Cq = Cq microRNA of interest - Cq reference control, 
Relative Quantification [RQ]=2-∆∆Cq and LOG transformed = 
LOG2RQ). Fold-change was logarithm-transformed as qPCR data 
are non-linear (exponential), and is transformed to decrease the 
heterogeneity of variance (McDonald, 2009) and also to identify 
the outliers present in the data (Rieu & Powers, 2009). Standard 
curves for three samples from both PAXM and MP were generated 
and a 95% confidence interval slope of the line was used to calcu-
late the PCR efficiency (E) using the standard formula; E=10-1/Slope 
and % efficiency = (E-1) × 100. Mean efficiency was then calcu-
lated. Results were analysed and plotted using GraphPad PRISM 
v5.0 software (GraphPad Software, Inc, USA). Mann-Whitney 
U t-test was used to assess difference between two groups and Kruskal-
Wallis one-way analysis of variance (ANOVA) for multiple groups. 
Spearman’s test was used to determine correlation. Bland-Altman 
was performed to test whether two methods agreed and if one could 
be interchanged with another. Significance was set at p<0.05.
Results
Quality of RNA extracts
Total RNA was extracted using three different extraction methods; 
PAXM (PAXgene Blood miRNA), MP (mirVana PARIS) and MM 
(miRVana miRNA) from whole blood and PBMCs. RNA purity 
was assessed by detecting the absorbance ratios at 260 nm/280 nm 
and at 260 nm/230 nm. The ratio (260 nm/280 nm) for whole blood 
was 1.95 – 2.35 and for isolated PBMCs was 2.00 – 2.27 (both MP 
and MM respectively). The ratios were ≥ 1.8 – 2.0; thus extraction 
was free from protein contamination which is usually absorbed at 
280 nm. Absorbance ratios detected at 260 nm/230 nm showed 
ratios below the accepted contamination-free range of 1.5 – 2.0 
(PBMCs: 0.18 – 1.83 and whole blood: 0.15 – 1.49). Therefore, 
the samples may have been affected by contaminants absorbed at 
230 nm such as guanidine isothiocyanate present in all the three 
extraction kits. For RNA purity, the peak of each total RNA plot 
was also analysed as it could indicate contamination by phenol and/
guanidine isothiocyanate. PBMCs had plot peaks at 260 nm thus 
confirming contaminant-free samples. However, peaks at 260 nm 
were absent for total RNA extracted using the PAXM (Figure 2). 
This further suggests that guanidine salts may have been the cause 
of contamination in whole blood samples extracted using PAXM.
Figure 2. Representative graphical plots of total RNA extracted. (A) PAXM: analysis of whole blood showed peaks positioned at 230 nm 
(n=10) and (B) MP: analysis of PBMCs showed peaks positioned at 260 nm (n=5).
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Figure 3. Expression of endogenous controls in total RNA 
extracted. A panel of four stably expressed miRNAs were selected 
and quantified to identify the most stable control for normalisation 
of miR-146a-5p and miR-155-5p in paired samples (n=3) (A) whole 
blood and (B) PBMCs. The standard error of the mean is shown by 
the error bars for demonstration of technical variability.
Quantitative PCR quality controls
NEC and NTC controls were used to ensure that the RT and qPCR 
reactions were contaminant-free. Each control displayed no ampli-
fication (Cq > 36). This was particularly important for total RNA 
extracted from PBMCs, as they were non-DNase treated. Thus, 
any amplification in the controls may have suggested either non-
specific binding of primers or presence of contamination such as 
genomic DNA. In addition we calculated the average efficiency of 
our real-time qPCR reactions (E=97.8%) which confirmed absence 
of reaction inhibitors such as heparin that was specifically used for 
the collection of peripheral blood from patients for the downstream 
PBMC isolation. (See Supplementary Figure 1, that shows there 
was no contamination in the samples with a Cq value equal to 40 
i.e. no amplification). Determining qPCR efficiency is important as 
inhibitory compounds can affect miRNA expression and result in 
false positives.
Reference control for microRNA expression in peripheral 
blood
We determined the most appropriate reference gene for this inves-
tigation by testing a panel of four controls that have been known 
for stable expression (SNORD49A [RNU49], SNRNP27 [U6], 
SNORA74A [RNU19] and SNORD48 [RNU48]) (Dataset a). Our 
results showed that SNORD48 expression was the most stable 
in total RNA extracted via both the PAXM (Figure 3A) and MP 
(Figure 3B) method. Therefore, SNORD48 was used as the refer-
ence control to normalise miR-146a-5p and miR-155-5p expression 
in each sample.
Whole blood extracted using PAXM exhibits higher degree 
of haemolysis
Erythrocyte haemolysis has been reported to alter miRNA measure-
ments in whole blood, plasma, serum and tissues (McDonald et al., 
2011; Pritchard et al., 2012). The total RNA extracted using the 
three different methods was examined for degree of haemolysis by 
quantifying miR-451-5p and miR-23a-3p (Dataset b). Normalised 
∆Cq values (miR-23a-3p – miR-451-5p) greater than seven were 
considered as an indicator of haemolysis. Our results showed that 
there was a significantly high degree of haemolysis in the total RNA 
extracted using the PAXM method with the ∆Cq values in the range 
of 9 – 11. Haemolysis was low in total RNA extracted using either 
of MP or MM, ∆Cq>3 (Figure 4).
MicroRNA expression in whole blood and PBMCs
With inclusion of stringent quality controls, we assessed miR-146a-5p 
and miR-155-5p expression in total RNA extracted in parallel 
from whole blood using PAXM (n=14) and PBMCs using MP 
(n=14) (Dataset c). Our results showed that there was no correla-
tion (Figure 5, miR-146a-5p: r=-0.352, p=0.217 and miR-155-5p: 
r=0.380, p=0.180) between PAXM and MP in the expression of both 
miR-146a-5p and miR-155-5p. In a PCR reaction, it is assumed that 
the target expression doubles at every reaction cycle. Bland-Altman 
analysis also showed that the two methods did not agree as the bias 
was greater than 1 which equated to more than one qPCR cycle dif-
ference between the two methods (Figure 5A and 5B). Mookherjee 
et al. had used MM to extract total RNA from PBMCs, then cor-
related miRNA expression between the PAXM and MM method 
Figure 4. Degree of haemoloysis in total RNA extracted via the 
three extraction methods. Total RNA extracted using the PAXgene 
miRNA isolation kit. A threshold of LOG2RQ greater than 7 was 
indicative of haemolysis (dashed line). The degree of haemolysis 
was calculated by measuring the difference between miR-451-5p and 
miR-23a-3p expression. All data (n=5) have been log-transformed. 
The standard error of the mean is shown by the error bars for 
demonstration of technical variability.
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(Mookherjee & El-Gabalawy, 2013). To eliminate the possibility 
that using MP was the reason for the non-correlation and disagree-
ment, we tested the three different extraction methods (PAXM, MP 
and MM) for both miRNAs in a randomly selected cohort of five 
healthy volunteers (Figure 6) (Dataset d). The results demonstrated 
that PAXM and MP as well as PAXM and MM did not correlate nor 
agreed with one another. However, MP and MM methods agreed 
with each other and could therefore be interchanged as the bias 
between the two methods for both miR-146a-5p and miR-155-5p 
was only 0.769 (SD=0.307) and 0.892 (SD=0.802), respectively. 
Interestingly, normalised miRNA expression was significantly dif-
ferent only between PAXM and MM methods (miR-146a-5p and 
miR-155-5p: p<0.01). There was higher miRNA expression in 
PBMCs than in whole blood for both miRNAs (Figure 7).
Figure 5. Bland-Altman plots for miRNA expression from whole blood and PBMCs. Total RNA was extracted (n=14) using PAXM and 
MP for (A) miR-146a-5p and (B) miR-155-5p expression. MicroRNA expression is within the limits of agreement but the bias is greater than 
one showing high disagreement between PAXM and MP. r indicates Spearman correlation. SD: Standard Deviation and bias is the mean 
difference. Cq values were used for this analysis. Dashed lines show the 95% lower and upper limits of agreement.
Figure 6. Bland-Altman plots for miR-146a-5p and miR-155-5p expression in whole blood and PBMCs. The three methods were all compared 
for miR-146a-5p as (A) PAXM vs MP (B) PAXM vs MM and (C) MP vs MM as well as miR-155-5p (D) PAXM vs MP (E) PAXM vs MM (F) MP vs MM. 
MicroRNA expression is within the limits of agreement but the bias is greater than one showing high disagreement between PAXM and MP. Bias 
is lower than one for MP and MM, thus the two methods agree with one another. r indicates Spearman correlation. SD: Standard Deviation and 
bias is the mean difference. Cq values were used for this analysis. Dashed lines show the 95% lower and upper limits of agreement.
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Dataset 1. Data of miRNA extraction methods from whole blood 
and PBMCs
http://dx.doi.org/10.5256/f1000research.4884.d33496
Dataset (a) shows the expression of all endogenous controls used in 
the study. Dataset (b) shows the degree of cell hemolysis using different 
extraction kits. Datasets (c)-(d)-(e) contain data of miR-146a-5p 
and miR-155-5p expression in whole blood and PBMCs in different 
samples. Complete dataset legends can be found in the text file.
Discussion
MicroRNA expression levels are used to classify diseases and also 
to distinguish the diseased from the healthy population. However, 
lack of uniform detection protocols has led to controversies and 
inconsistencies in miRNA research. There is also lack of recogni-
tion for the presence of miRNAs from erythrocytes and other cell-
types when using whole blood for total RNA extraction processes 
and downstream miRNA studies. In most investigations, PBMCs 
are considered as the major cellular sources for miRNAs. This 
work was conducted to elucidate the difference between total 
RNA extracted from whole blood and PBMCs for miRNA expres-
sion level studies and also to highlight the importance of protocol 
standardization.
RT-qPCR was performed to examine whether the expression of 
miR-146a-5p and miR-155-5p in whole blood and PBMC agreed 
with one another. Our results showed that there was no agreement 
between PAXM and both MP and MM for miR-146a-5p and miR-
155-5p expression. PBMCs constitute only a fraction of the cells 
present in PB and therefore lack granulocytes, platelets and eryth-
rocytes (Min et al., 2010). Due to the unique miRNA expression 
pattern in each cell-type the relative proportions of cells in blood 
may have an effect on the overall miRNA expression profile and 
the expression of their protein targets (Min et al., 2010). Some 
studies have shown that mature miRNA expression signature in 
erythrocytes is similar to that in whole blood while different when 
compared to PBMCs (Chen et al., 2008). MiR-451-5p is a marker 
of erythrocytes (Rasmussen et al., 2010) and miR-23a-3p is unaf-
fected by haemolysis (Blondal et al., 2013). We have shown that 
there is lower miR-146a-5p and miR-155-5p expression in whole 
blood compared to PBMCs demonstrating that the total RNA 
extracted from PBMCs does not reflect that detected in whole 
blood. Several studies have shown that total RNA yield from whole 
blood decreases after the use of DNase step in the PAXM protocol 
(Asare et al., 2008; Bayatti et al., 2014; Debey et al., 2004). However, 
if PAXM total RNA is not DNase-treated, there may be a possibility 
of DNA contamination. Contrary to our results, Mookherjee et al. 
found a linear correlation between miR146a-5p and miR-155-5p 
expression in whole blood and isolated PBMCs collected from a 
healthy population (Mookherjee & El-Gabalawy, 2013). In their 
work, they did not measure the degree of haemolysis in the samples, 
which may partly explain the discrepancy between the two studies. 
Furthermore, our study compared both the strength (correlation) 
and level of agreement between the two methods whilst Mookherjee 
et al. examined only the correlation (Bland & Altman, 1986). This 
highlights the importance of performing the correct statistics when 
two methods are compared with regards to their equivalence and 
interchangeability (Burd, 2010).
In clinical practice, it is easier to collect PB in PAXgene Blood 
RNA tubes as they have a shelf-life of two to five years without 
any RNA degradation. Immediate stabilisation is vital as stor-
age of blood cells induce changes in the miRNA composition 
Figure 7. Normalised miRNA expression comparison from whole blood and PBMCs. (A) miR-146a-5p and (B) miR-155-5p expression. 
MicroRNA expression is significantly varied across all the three different groups (p=0.002). MicroRNA expression is higher in PBMCs extracted 
via either MP or MM method in comparison to whole blood. **p<0.01 and ns: not significant.
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(Gaarz et al., 2010). Thus, extraction methods from whole blood 
must be optimised to either eliminate erythrocyte contamination 
or consider the expression as cumulative and design downstream 
experiments for miRNA protein target studies accordingly.
In conclusion, our study showed differences in miR-146a-5p and 
miR-155-5p expression in isolated PBMCs and whole blood. We 
suggest that PBMCs are not the ideal source to study and corre-
late miRNA protein targets where the miRNA expression had been 
measured in whole blood as the miRNA expression pattern in whole 
blood is not comparable to that in PBMCs. We also highlight the 
importance of having a stringent set of technical controls and per-
forming the correct statistics to increase the reliability and repro-
ducibility of miRNA expression studies.
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Open Peer Review
   Current Referee Status:
Version 3
 24 September 2015Referee Report
doi:10.5256/f1000research.7159.r10479
 Stefano Casola
Genetics and Epigenetics of Lymphocyte Development and Transformation Research Program, Institute
of Molecular Oncology Foundation (IFOM Institute), Milan, Italy
In this manuscript, Atarod and colleagues quantify the expression levels of two candidate miRNAs,
mir-146-5p and mir-155-5p, starting from either whole blood (WB) or PBMC.  Authors employ quantitative
real-time PCR to measure candidate miRNA transcripts from the two biological sources. Different
procedures were used to extract total RNA from the two sources, which could, at least in part, affect
downstream expression analyses.  The study is sound and the data are convincing and relevant for
appropriate selection of the blood source from which to measure levels of miRNAs of interest. The
conclusions reached by the authors indicate poor correspondence in the expression of mir-146-5p and
mir-155-5p when comparing WB to PBMC as biological source. The results by Atarod and colleagues are
in apparent contrast with those described in a previous study by Mookherjee & El-Gabalawy. The
reasoning to explain the discrepancy is convincing, and raises important issues related to technical
(grade of haemolysis) and methodological aspects (statistical analysis) of the expression analysis that
could undermine a correct interpretation of the data.
 
The title is appropriate and data are presented and discussed in a concise and clear fashion.
 
The manuscript has benefited from previous rounds of revision, addressing the main concerns raised by
the reviewers.
 
Minor points:
Materials and methods section:
Sample collection and storage: Authors state that, after purification, PBMCs were stored at -4 C. Is°
that correct? Or, instead it should read +4°C?
 
Authors state “PBMC were cryopreserved by re-suspension in freezing solution containing 350 ml 
Authors should replace “350 ml” with (I suspect) 350µl.of RPMI 1640..” 
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
Author Response 25 Sep 2015
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Author Response 25 Sep 2015
, Newcastle University, UK, UKSadaf Atarod
Thank you for reviewing our manuscript and your valuable comments. Please, find below our
replies.
1. We stored the cells on ice, as the extraction was performed soon after the collection. This
information has been updated in the revised manuscript.
2. We have updated the revised manuscript with the percentage of each ingredient. We used 70%
RPMI to make up the freezing solution. 
 None.Competing Interests:
 23 June 2015Referee Report
doi:10.5256/f1000research.7159.r9135
 Steven O'Reilly
School of Biological and Biomedical Sciences, Durham University, Durham, UK
In light of the new version and the author’s response to my , I am happy to approve thisprevious review
article.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
Version 2
 14 May 2015Referee Report
doi:10.5256/f1000research.6331.r8664
 Steven O'Reilly
School of Biological and Biomedical Sciences, Durham University, Durham, UK
This is a very interesting an important study that highlights differences in microRNA expression between
whole blood and isolated Peripheral Blood Mononuclear Cells (PBMCs). This is of clear importance
where as many authors would be using whole blood microRNA expression and then using isolated
PBMCs to draw conclusions on their putative targets. There is clear differences between the two due to
the fact of other sources of microRNAs in the whole blood including erythrocytes and platelets and the
fact that there are also ‘free floating’ microRNAs in blood also, likely encased in exosomes. This study is
technically sound and I particularly like the fact that the authors calculated the qPCR efficiency. The
design is also technically sound.
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I would suggest that the authors include a ‘screen shot’ of the actual amplification curve of the No
Template Control (NTC).  This will confirm visually that there is no contamination in the samples with a
likely CT value 37>.
Did the authors after lymphoprep isolation notice any difference in expression of the microRNAs before
and after cryopreservation?  The cryopreservation medium contains DMSO (although low) and we have
found this affects certain microRNA expression patterns.
Was there any apparent difference in the levels of the microRNAs correlation with age? I.e. old donors
had lower or higher levels of miR-146a because they are immunosenescent (but not diseased)?
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
 No competing interests were disclosed.Competing Interests:
Author Response 12 Jun 2015
, Newcastle University, UK, UKSadaf Atarod
Thank you for reviewing our manuscript and your valuable comments. Please, find below our
replies.
1. I would suggest that the authors include a ‘screen shot’ of the actual amplification curve of the
No Template Control (NTC). This will confirm visually that there is no contamination in the samples
with a likely CT value 37>.
Thanks for the suggestion. This figure has been added as a supplementary figure to the
manuscript.
2. Did the authors after lymphoprep isolation notice any difference in expression of the microRNAs
before and after cryopreservation? The cryopreservation medium contains DMSO (although low)
and we have found this affects certain microRNA expression patterns.
We have evaluated the impact of cryopreservation on miRNA expression by extracting total RNA
from paired fresh and cryopreserved PBMCs (n=5) and performed RT-qPCR respectively. There
was no significant difference between fresh and cryopreserved PBMCs for the expression of
miR-146a-5p and miR-155-5p (both p=0.125). For the figure, please refer to the first version of this
paper. In addition, there was no correlation in miRNA expression between fresh and cryopreserved
PBMCs with the bias of <1 for both miR-146a-5p and miR-155-5p.Thus, in this study, expressions
of miR-146a-5p and miR-155-5p in fresh and cryopreserved PBMCs agreed with one another
although further studies including more samples and longer period of cryopreservation may
provide more informative evidence. Moreover, this finding may not be generalised to other miRNAs
as individual miRNAs may have varied susceptibility to cryopreservation.
3. Was there any apparent difference in the levels of the microRNAs correlation with age? I.e. old
donors had lower or higher levels of miR-146a because they are immunosenescent (but not
diseased)?
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In this investigation, there was no correlation between age and miRNA expression levels.
However, this investigation cohort included only three older volunteers (age> 55 years). Thus, this
finding requires further confirmation in a larger cohort of samples and with older age. 
 No competing interest to declare.Competing Interests:
Version 1
 17 October 2014Referee Report
doi:10.5256/f1000research.5214.r6354
 Kenneth Witwer
Molecular and Comparative Pathobiology, Johns Hopkins University, Baltimore, MD, USA
The design of this study is flawed, and several conclusions are not justified by the results. Since the PCR
technique seems sound (and the authors are commended for including information such as PCR
efficiency), there may be several subcomponents of the study that could be separated out and published
as a smaller paper (e.g., the results of the gender and freezing experiments).
I would encourage the authors to remove immediately the baseless claims about putative problems 
with the PAXgene reagents or protocol. A major (and wrong) conclusion of the paper is that the
PAXgene method results in putatively excessive hemolysis, or, as the Figure 4 title incorrectly
states, "Erythrocyte contamination". The putative difference from the other methods is described
as "significantly" high, and although no statistical analysis is reported, one could hardly quibble
with a ten-order-of-magnitude difference. However, this difference has nothing to do with
hemolysis as a processing variable and in fact reflects well, not poorly, on the PAXgene method.
The PAXgene tube is designed to lyse blood cells and stabilize RNA. This study is thus not an
examination of methods, hemolysis or RBC contamination! It is simply a confirmation that lysed
RBCs contain RBC RNA, whereas PBMCs do not contain RBC RNA.
 
There appears to be a fundamental confusion about what constitutes hemolysis vs. red blood cell
contamination. Where is the evidence that "haemolysis has been reported to alter miRNA
measurements in whole blood, plasma, serum, and tissues"? The two cited references examine
the effects of hemolysis in plasma and serum, where lysis of cells can indeed have a great effect. It
is clear that the very low abundance extracellular RNA fraction of blood is influenced by an influx of
cellular RNA. It is unclear how degree of hemolysis could affect detection of very high abundance
cellular miRNAs in whole blood (where erythrocytes dominate anyway) or in cells like PBMC that
are purified away from other components.
 
The title does not describe the study. The study is presented incorrectly as a comparison of RNA
extraction methods and of RNA expression in whole blood and PBMCs. Unfortunately, too many
variables are changed at once in the study to allow any conclusions to be drawn. For example (see
Figure 1): substrate type (whole blood vs PBMC); initial treatment (PAXgene tube for whole blood,
heparin for PBMC); cell isolation (none for whole blood, centrifugation over a gradient for PBMC);
and RNA isolation method (PAXgene for whole blood, two nearly identical Ambion kits for PBMC).
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and RNA isolation method (PAXgene for whole blood, two nearly identical Ambion kits for PBMC).
The only variable that can be isolated is the use of the mirVana PARIS vs miRNA kit.
 
Heparin, as a PCR inhibitor, may not be the best anticoagulant for use in qPCR-based studies. No
special steps are described for removal of heparin.
Minor points
There are no error bars to indicate biological or technical variability in Figure 3 or 4.
 
The workflow of Figure 1 does not indicate that the right-hand-side pathway involved only PBMC,
not whole blood.
 
The PAXgene Blood RNA Tube and the PAXgene Blood miRNA Kit are presented as the "gold
standard" in the field, yet the citation is a publication by the company, and it does not mention the
miRNA kit. This should be replaced by a more objective assessment.
 
More clarity is needed in the use of terms. For example, there may or may not be RNA
"expression" differences between genders or cell types. In contrast, differences in RNA
quantitation observed upon freezing, or addition of PCR inhibitors, or after purification of the same
sample with different kits, are not due to "expression" differences. The underlying expression in the
cell remains the same; the ability to characterize it changes.
 
Citations of the literature are somewhat thin.
I have read this submission. I believe that I have an appropriate level of expertise to state that I
do not consider it to be of an acceptable scientific standard, for reasons outlined above.
 No competing interests were disclosed.Competing Interests:
Author Response 01 Dec 2014
, Newcastle University, UK, UKSadaf Atarod
Thanks for the valuable comments. We admit full heartedly that some descriptions and statements
in the text were not as clear as they should be. This has caused misunderstanding and confusion.
 Good efforts have been given to improve the clarity of the text and to address each comment by
the reviewer. We hope the revised manuscript could convince the reviewer (and the readers) that
the design of the study is sound and rational and the conclusions can be well justified by the
results.
As suggested, the results of gender and cryopreservation experiments have been excluded to
deliver a more focused message.
The title of the manuscript has also been changed to clarify the message of the
 
"I would encourage the authors to remove immediately the baseless claims about putative
problems with the PAXgene reagents or protocol. A major (and wrong) conclusion of the
paper is that the PAXgene method results in putatively excessive hemolysis, or, as the
Figure 4 title incorrectly states, "Erythrocyte contamination". The putative difference from the
other methods is described as "significantly" high, and although no statistical analysis is
reported, one could hardly quibble with a ten-order-of-magnitude difference. However, this
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reported, one could hardly quibble with a ten-order-of-magnitude difference. However, this
difference has nothing to do with hemolysis as a processing variable and in fact reflects
well, not poorly, on the PAXgene method. The PAXgene tube is designed to lyse blood cells
and stabilize RNA. This study is thus not an examination of methods, hemolysis or RBC
contamination! It is simply a confirmation that lysed RBCs contain RBC RNA, whereas
PBMCs do not contain RBC RNA." 
This article has no intention at all to claim any problems with the PAXgene protocol or to
examine haemolysis or RBC contamination. The key points we intended to raise in this
manuscript are 1) the use of total RNA extracted from whole blood or isolated PBMC could
lead to differential results of miRNA quantification as miRNAs expressed in erythrocytes are
present in total RNAs extracted from whole blood but not isolated PBMCs; 2) This inevitable
fact is partly accountable for many conflicting reports in the existing literatures; 3) This is an
important factor that researchers should consider when conducting miRNA research so as
to extract total RNAs from most appropriate starting material (whole blood or isolated
PBMC). Particularly, total RNAs extracted from the same starting material should be used
for analysis of specific miRNAs and their downstream protein targets. These points have
been clarified in the revised manuscript.
Furthermore, Figure 4 was intended to demonstrate the fact that erythrocyte related miRNA
is present and detectable when using total RNAs extracted from whole blood (not to show
red blood cell contamination). The title of Figure 4 and the related contents in the text have
been revised to clarify this point that it is not a contamination but a factor that needsper se 
to be considered when analysing, reporting results and investigating miRNA protein targets.
 
"There appears to be a fundamental confusion about what constitutes hemolysis vs. red
blood cell contamination. Where is the evidence that "haemolysis has been reported to alter
miRNA measurements in whole blood, plasma, serum, and tissues"? The two cited
references examine the effects of hemolysis in plasma and serum, where lysis of cells can
indeed have a great effect. It is clear that the very low abundance extracellular RNA fraction
of blood is influenced by an influx of cellular RNA. It is unclear how degree of hemolysis
could affect detection of very high abundance cellular miRNAs in whole blood (where
erythrocytes dominate anyway) or in cells like PBMC that are purified away from other
components."
We believe this is a confusion caused by the inappropriate use of terminology rather than a
flaw in study design. The revised manuscript has clarified these points. The discussion point
of the manuscript is neither about haemolysis nor red blood cell contamination but simply
about the fact that the presence of red blood cells in whole blood method may give rise to
different miRNA quantification results compared to those where isolated PBMCs were used
to extract total RNAs.
 
"The title does not describe the study. The study is presented incorrectly as a comparison of
RNA extraction methods and of RNA expression in whole blood and PBMCs. Unfortunately,
too many variables are changed at once in the study to allow any conclusions to be drawn.
For example (see Figure 1): substrate type (whole blood vs PBMC); initial treatment
(PAXgene tube for whole blood, heparin for PBMC); cell isolation (none for whole blood,
centrifugation over a gradient for PBMC); and RNA isolation method (PAXgene for whole
blood, two nearly identical Ambion kits for PBMC). The only variable that can be isolated is
the use of the mirVana PARIS vs miRNA kit." 
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the use of the mirVana PARIS vs miRNA kit." 
This study was not a comparison of RNA extraction methods. The aim of this study was to
find out whether miR-146a-5p and miR-155-5p expression detected in PBMCs mirrored that
quantified in total RNA extracted from whole blood. For this reason two main extraction
methods had to be used one for extraction from whole blood and the other from PBMCs.
Our results clarified the misconceptions reported in the literature suggesting that the levels
of miRNAs detected in whole blood and PBMCs correlate with each other. In fact
miR-146a-5p and miR-155-5p are both miRNAs that are detectable in acellular sources
such as serum and plasma which again reiterates that the miRNA expression quantified in
whole blood would be varied from that of PBMCs.
 
"Heparin, as a PCR inhibitor, may not be the best anticoagulant for use in qPCR-based
studies. No special steps are described for removal of heparin."
The use of Heparin in this study was driven by the logic that Heparin is one of the most
commonly used anti-coagulants for collecting PBMCs from clinical samples. We reported
over 90% efficiency of the PCR reactions demonstrating the fact that the data presented in
this study had not been compromised by the use of Heparin. The quality of RNA was also
high as the 260/280 ratios were above 1.8 as stated in the manuscript.
Minor points
"There are no error bars to indicate biological or technical variability in Figure 3 or 4. "
Error bars have been added to illustrate technical variability in Figure 3 and Figure 4,
respectively. As the variability is very small the error bars are hardly visible, hence inserted
the sentence “The error bars represent technical variability” in the figure legends.
 
"The workflow of Figure 1 does not indicate that the right-hand-side pathway involved only
PBMC, not whole blood." 
The workflow of Figure 1 has been modified with an added step to indicate that the
right-hand-side pathway involved only PBMCs and not whole blood.
 
"The PAXgene Blood RNA Tube and the PAXgene Blood miRNA Kit are presented as the
"gold standard" in the field, yet the citation is a publication by the company, and it does not
mention the miRNA kit. This should be replaced by a more objective assessment."
The company reference has been substituted with an original research article by Viprey et al
 (2012) which highlights the reliability and suitability of the whole blood collection method
using the PAXgene Blood RNA tubes. It is worth noting that the focus of this report is to
evaluate the effect of using total RNAs collected via the PAXgene Blood RNA protocol on
miRNA quantification rather than on mRNA expressions.
 
"More clarity is needed in the use of terms. For example, there may or may not be RNA
"expression" differences between genders or cell types. In contrast, differences in RNA
quantitation observed upon freezing, or addition of PCR inhibitors, or after purification of the
same sample with different kits, are not due to "expression" differences. The underlying
expression in the cell remains the same; the ability to characterize it changes."
Great attention has been given to using terms with clarity and accuracy in the revised
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Great attention has been given to using terms with clarity and accuracy in the revised
manuscript.  
 
"Citations of the literature are somewhat thin."
In contrast to mRNA research where large pools of literatures have investigated numerous
factors that could impact on the outcome of mRNA quantification, the miRNA research is
still at its infancy and very few studies have investigated the impact of various total RNA
extraction methods on the outcome of miRNA quantification although many articles have
been published reporting associations of differential miRNA expression with diagnostic or
prognostic status of diseases. This manuscript is particularly aimed to inform the miRNA
community that different sources and methods used for extracting total RNAs could have
significant impact on the outcome of miRNA quantification.
 No competing interests to declare.Competing Interests:
Page 17 of 17
F1000Research 2015, 3:183 Last updated: 07 OCT 2015
